rulonilimab + paclitaxel + carboplatin

Rulonilimab + paclitaxel + carboplatin is a **combination drug regimen** used or studied for the treatment of several cancers, notably advanced or metastatic non-small cell lung cancer (NSCLC) and cervical cancer. - **Rulonilimab** is a recombinant humanized IgG4 monoclonal antibody against programmed cell death-1 (PD-1), functioning as a checkpoint inhibitor to block PD-1 and activate T lymphocytes for an enhanced immune anti-tumor response. It is also capable of antibody-dependent cell cytotoxicity (ADCC)[3][5]. - **Paclitaxel** is a microtubule-stabilizing antineoplastic small molecule that induces mitotic arrest and apoptosis in tumor cells[2][4][6]. - **Carboplatin** is a platinum-based DNA crosslinker causing cell cycle arrest and apoptosis; it is widely used alongside paclitaxel in various solid tumors including NSCLC and ovarian cancer[2][4][6]. This regimen brings together **immune checkpoint inhibition** and **cytotoxic chemotherapy**, leveraging complementary mechanisms: direct tumor cell killing by chemotherapy and immune system activation by PD-1 blockade. It is primarily in clinical development for advanced/metastatic NSCLC and cervical cancer[3][5].